Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 80,852 shares of Werewolf Therapeutics stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $0.48, for a total value of $38,808.96. Following the completion of the transaction, the director directly owned 682,833 shares of the company’s stock, valued at $327,759.84. This represents a 10.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Luke Evnin also recently made the following trade(s):
- On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $14,650.20.
- On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.46, for a total value of $12,741.08.
- On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total value of $31,936.50.
- On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total value of $39,341.25.
- On Thursday, May 21st, Luke Evnin sold 36,387 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.42, for a total value of $15,282.54.
- On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.43, for a total value of $36,934.85.
- On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $28,336.50.
- On Monday, May 18th, Luke Evnin sold 22,184 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.50, for a total value of $11,092.00.
- On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $43,446.40.
- On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total value of $22,745.16.
Werewolf Therapeutics Price Performance
Shares of Werewolf Therapeutics stock traded down $0.01 on Friday, hitting $0.45. 278,763 shares of the company’s stock traded hands, compared to its average volume of 463,613. Werewolf Therapeutics, Inc. has a one year low of $0.40 and a one year high of $2.38. The company has a fifty day moving average of $0.75 and a two-hundred day moving average of $0.75. The company has a market capitalization of $21.87 million, a price-to-earnings ratio of -0.36 and a beta of 0.41.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Regal Investment Advisors LLC lifted its holdings in shares of Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after acquiring an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. lifted its holdings in shares of Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after acquiring an additional 24,003 shares during the last quarter. Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at about $48,000. AQR Capital Management LLC bought a new position in shares of Werewolf Therapeutics in the 1st quarter valued at about $79,000. Finally, Bridgeway Capital Management LLC lifted its holdings in shares of Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after acquiring an additional 62,414 shares during the last quarter. Institutional investors own 64.84% of the company’s stock.
Analyst Ratings Changes
Several brokerages recently commented on HOWL. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Wall Street Zen downgraded Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $3.75.
View Our Latest Stock Report on Werewolf Therapeutics
About Werewolf Therapeutics
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Featured Stories
- Five stocks we like better than Werewolf Therapeutics
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
